Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 439781 [uid] => 2032 [title] => Unipd study investigates the development of treatments against SARS-CoV-2 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104738 [type] => box_lancio_news [language] => it [created] => 1698150678 [changed] => 1698150568 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1698150568 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine of the University of Padua, aims to investigate the development of effective treatments against SARS-CoV-2 infection.

Published in the Journal of Clinical Medicine, the results of the RACONA study demonstrate the efficacy and safety of the protease inhibitor nafamostat, in the therapeutic treatment against Sars-CoV-2, a disease that still affects a number of fragile people that may require hospitalization and a high-level of health care.

The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection.

Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. 

The results of an ad interim safety analysis showed similar overall trends for variables evaluating renal function, coagulation, and inflammation. Used for the first time in Europe, no drug adverse events were observed during treatment in any patients.  In the RACONA study, nafamostat showed a good safety profile and, therefore, could represent an effective tool, particularly against those variants that are more dependent on TMPRSS2 (e.g., omicron vs. delta variant).

[summary] => [format] => 2 [safe_value] =>

The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine of the University of Padua, aims to investigate the development of effective treatments against SARS-CoV-2 infection.

Published in the Journal of Clinical Medicine, the results of the RACONA study demonstrate the efficacy and safety of the protease inhibitor nafamostat, in the therapeutic treatment against Sars-CoV-2, a disease that still affects a number of fragile people that may require hospitalization and a high-level of health care.

The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection.

Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. 

The results of an ad interim safety analysis showed similar overall trends for variables evaluating renal function, coagulation, and inflammation. Used for the first time in Europe, no drug adverse events were observed during treatment in any patients.  In the RACONA study, nafamostat showed a good safety profile and, therefore, could represent an effective tool, particularly against those variants that are more dependent on TMPRSS2 (e.g., omicron vs. delta variant).

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124087 [uid] => 2032 [filename] => n_covid_ricerca_1.jpg [uri] => public://n_covid_ricerca_1_0.jpg [filemime] => image/jpeg [filesize] => 17968 [status] => 1 [timestamp] => 1698150678 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => covid [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine, aims to investigate the development of effective treatments against SARS-CoV-2 infection [format] => [safe_value] => The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine, aims to investigate the development of effective treatments against SARS-CoV-2 infection ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2024-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 439781 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine of the University of Padua, aims to investigate the development of effective treatments against SARS-CoV-2 infection.

Published in the Journal of Clinical Medicine, the results of the RACONA study demonstrate the efficacy and safety of the protease inhibitor nafamostat, in the therapeutic treatment against Sars-CoV-2, a disease that still affects a number of fragile people that may require hospitalization and a high-level of health care.

The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection.

Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. 

The results of an ad interim safety analysis showed similar overall trends for variables evaluating renal function, coagulation, and inflammation. Used for the first time in Europe, no drug adverse events were observed during treatment in any patients.  In the RACONA study, nafamostat showed a good safety profile and, therefore, could represent an effective tool, particularly against those variants that are more dependent on TMPRSS2 (e.g., omicron vs. delta variant).

[summary] => [format] => 2 [safe_value] =>

The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine of the University of Padua, aims to investigate the development of effective treatments against SARS-CoV-2 infection.

Published in the Journal of Clinical Medicine, the results of the RACONA study demonstrate the efficacy and safety of the protease inhibitor nafamostat, in the therapeutic treatment against Sars-CoV-2, a disease that still affects a number of fragile people that may require hospitalization and a high-level of health care.

The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection.

Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. 

The results of an ad interim safety analysis showed similar overall trends for variables evaluating renal function, coagulation, and inflammation. Used for the first time in Europe, no drug adverse events were observed during treatment in any patients.  In the RACONA study, nafamostat showed a good safety profile and, therefore, could represent an effective tool, particularly against those variants that are more dependent on TMPRSS2 (e.g., omicron vs. delta variant).

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine of the University of Padua, aims to investigate the development of effective treatments against SARS-CoV-2 infection.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 439781 [uid] => 2032 [title] => Unipd study investigates the development of treatments against SARS-CoV-2 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104738 [type] => box_lancio_news [language] => it [created] => 1698150678 [changed] => 1698150568 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1698150568 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine of the University of Padua, aims to investigate the development of effective treatments against SARS-CoV-2 infection.

Published in the Journal of Clinical Medicine, the results of the RACONA study demonstrate the efficacy and safety of the protease inhibitor nafamostat, in the therapeutic treatment against Sars-CoV-2, a disease that still affects a number of fragile people that may require hospitalization and a high-level of health care.

The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection.

Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. 

The results of an ad interim safety analysis showed similar overall trends for variables evaluating renal function, coagulation, and inflammation. Used for the first time in Europe, no drug adverse events were observed during treatment in any patients.  In the RACONA study, nafamostat showed a good safety profile and, therefore, could represent an effective tool, particularly against those variants that are more dependent on TMPRSS2 (e.g., omicron vs. delta variant).

[summary] => [format] => 2 [safe_value] =>

The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine of the University of Padua, aims to investigate the development of effective treatments against SARS-CoV-2 infection.

Published in the Journal of Clinical Medicine, the results of the RACONA study demonstrate the efficacy and safety of the protease inhibitor nafamostat, in the therapeutic treatment against Sars-CoV-2, a disease that still affects a number of fragile people that may require hospitalization and a high-level of health care.

The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection.

Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. 

The results of an ad interim safety analysis showed similar overall trends for variables evaluating renal function, coagulation, and inflammation. Used for the first time in Europe, no drug adverse events were observed during treatment in any patients.  In the RACONA study, nafamostat showed a good safety profile and, therefore, could represent an effective tool, particularly against those variants that are more dependent on TMPRSS2 (e.g., omicron vs. delta variant).

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124087 [uid] => 2032 [filename] => n_covid_ricerca_1.jpg [uri] => public://n_covid_ricerca_1_0.jpg [filemime] => image/jpeg [filesize] => 17968 [status] => 1 [timestamp] => 1698150678 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => covid [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine, aims to investigate the development of effective treatments against SARS-CoV-2 infection [format] => [safe_value] => The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine, aims to investigate the development of effective treatments against SARS-CoV-2 infection ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2024-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 439781 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124087 [uid] => 2032 [filename] => n_covid_ricerca_1.jpg [uri] => public://n_covid_ricerca_1_0.jpg [filemime] => image/jpeg [filesize] => 17968 [status] => 1 [timestamp] => 1698150678 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => covid [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 124087 [uid] => 2032 [filename] => n_covid_ricerca_1.jpg [uri] => public://n_covid_ricerca_1_0.jpg [filemime] => image/jpeg [filesize] => 17968 [status] => 1 [timestamp] => 1698150678 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => covid [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 439781 [uid] => 2032 [title] => Unipd study investigates the development of treatments against SARS-CoV-2 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104738 [type] => box_lancio_news [language] => it [created] => 1698150678 [changed] => 1698150568 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1698150568 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine of the University of Padua, aims to investigate the development of effective treatments against SARS-CoV-2 infection.

Published in the Journal of Clinical Medicine, the results of the RACONA study demonstrate the efficacy and safety of the protease inhibitor nafamostat, in the therapeutic treatment against Sars-CoV-2, a disease that still affects a number of fragile people that may require hospitalization and a high-level of health care.

The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection.

Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. 

The results of an ad interim safety analysis showed similar overall trends for variables evaluating renal function, coagulation, and inflammation. Used for the first time in Europe, no drug adverse events were observed during treatment in any patients.  In the RACONA study, nafamostat showed a good safety profile and, therefore, could represent an effective tool, particularly against those variants that are more dependent on TMPRSS2 (e.g., omicron vs. delta variant).

[summary] => [format] => 2 [safe_value] =>

The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine of the University of Padua, aims to investigate the development of effective treatments against SARS-CoV-2 infection.

Published in the Journal of Clinical Medicine, the results of the RACONA study demonstrate the efficacy and safety of the protease inhibitor nafamostat, in the therapeutic treatment against Sars-CoV-2, a disease that still affects a number of fragile people that may require hospitalization and a high-level of health care.

The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection.

Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. 

The results of an ad interim safety analysis showed similar overall trends for variables evaluating renal function, coagulation, and inflammation. Used for the first time in Europe, no drug adverse events were observed during treatment in any patients.  In the RACONA study, nafamostat showed a good safety profile and, therefore, could represent an effective tool, particularly against those variants that are more dependent on TMPRSS2 (e.g., omicron vs. delta variant).

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124087 [uid] => 2032 [filename] => n_covid_ricerca_1.jpg [uri] => public://n_covid_ricerca_1_0.jpg [filemime] => image/jpeg [filesize] => 17968 [status] => 1 [timestamp] => 1698150678 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => covid [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine, aims to investigate the development of effective treatments against SARS-CoV-2 infection [format] => [safe_value] => The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine, aims to investigate the development of effective treatments against SARS-CoV-2 infection ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2024-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 439781 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine, aims to investigate the development of effective treatments against SARS-CoV-2 infection [format] => [safe_value] => The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine, aims to investigate the development of effective treatments against SARS-CoV-2 infection ) ) [#formatter] => text_default [0] => Array ( [#markup] => The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine, aims to investigate the development of effective treatments against SARS-CoV-2 infection ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Unipd study investigates the development of treatments against SARS-CoV-2 [href] => node/104738 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Unipd study investigates the development of treatments against SARS-CoV-2 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 439781 [uid] => 2032 [title] => Unipd study investigates the development of treatments against SARS-CoV-2 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104738 [type] => box_lancio_news [language] => it [created] => 1698150678 [changed] => 1698150568 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1698150568 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine of the University of Padua, aims to investigate the development of effective treatments against SARS-CoV-2 infection.

Published in the Journal of Clinical Medicine, the results of the RACONA study demonstrate the efficacy and safety of the protease inhibitor nafamostat, in the therapeutic treatment against Sars-CoV-2, a disease that still affects a number of fragile people that may require hospitalization and a high-level of health care.

The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection.

Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. 

The results of an ad interim safety analysis showed similar overall trends for variables evaluating renal function, coagulation, and inflammation. Used for the first time in Europe, no drug adverse events were observed during treatment in any patients.  In the RACONA study, nafamostat showed a good safety profile and, therefore, could represent an effective tool, particularly against those variants that are more dependent on TMPRSS2 (e.g., omicron vs. delta variant).

[summary] => [format] => 2 [safe_value] =>

The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine of the University of Padua, aims to investigate the development of effective treatments against SARS-CoV-2 infection.

Published in the Journal of Clinical Medicine, the results of the RACONA study demonstrate the efficacy and safety of the protease inhibitor nafamostat, in the therapeutic treatment against Sars-CoV-2, a disease that still affects a number of fragile people that may require hospitalization and a high-level of health care.

The protease inhibitor nafamostat, currently used in Japan and Korea for pancreatitis, owing to its anticoagulant properties for disseminated intravascular coagulation (DIC), is appealing for the treatment of COVID-19 infection, because it potently inhibits the transmembrane protease serine 2 (TMPRSS2) that, after virus binding to ACE-2, allows virus entry into the cells and replication. Moreover, it could prevent the DIC and pulmonary embolism frequently associated with COVID-19 infection.

Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. 

The results of an ad interim safety analysis showed similar overall trends for variables evaluating renal function, coagulation, and inflammation. Used for the first time in Europe, no drug adverse events were observed during treatment in any patients.  In the RACONA study, nafamostat showed a good safety profile and, therefore, could represent an effective tool, particularly against those variants that are more dependent on TMPRSS2 (e.g., omicron vs. delta variant).

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124087 [uid] => 2032 [filename] => n_covid_ricerca_1.jpg [uri] => public://n_covid_ricerca_1_0.jpg [filemime] => image/jpeg [filesize] => 17968 [status] => 1 [timestamp] => 1698150678 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => covid [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine, aims to investigate the development of effective treatments against SARS-CoV-2 infection [format] => [safe_value] => The RAndomized Clinical Trial Of NAfamostat (RACONA) study, conducted by a University of Padua research team coordinated by Gian Paolo Rossi and Teresa Maria Seccia of the Department of Medicine, aims to investigate the development of effective treatments against SARS-CoV-2 infection ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2024-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 439781 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Mar, 24/10/2023 ) ) )

Array ( [field_link_esterno_news] => Array ( [#theme] => field [#weight] => -1 [#title] => Link esterno news [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_link_esterno_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 439764 [uid] => 2032 [title] => Paolo Bonato, guest at the Seminars series organized by PNC and DNS [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104735 [type] => box_lancio_news [language] => it [created] => 1698147067 [changed] => 1698147067 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1698147067 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[summary] => [format] => 2 [safe_value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124085 [uid] => 2032 [filename] => n_neuroscienze.jpg [uri] => public://n_neuroscienze_0.jpg [filemime] => image/jpeg [filesize] => 72438 [status] => 1 [timestamp] => 1698147067 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => neuroscience [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM [format] => [safe_value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2023-11-03T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 439764 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) [#formatter] => text_default [0] => Array ( [#markup] => ) ) [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 439764 [uid] => 2032 [title] => Paolo Bonato, guest at the Seminars series organized by PNC and DNS [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104735 [type] => box_lancio_news [language] => it [created] => 1698147067 [changed] => 1698147067 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1698147067 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[summary] => [format] => 2 [safe_value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124085 [uid] => 2032 [filename] => n_neuroscienze.jpg [uri] => public://n_neuroscienze_0.jpg [filemime] => image/jpeg [filesize] => 72438 [status] => 1 [timestamp] => 1698147067 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => neuroscience [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM [format] => [safe_value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2023-11-03T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 439764 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[summary] => [format] => 2 [safe_value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 439764 [uid] => 2032 [title] => Paolo Bonato, guest at the Seminars series organized by PNC and DNS [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104735 [type] => box_lancio_news [language] => it [created] => 1698147067 [changed] => 1698147067 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1698147067 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[summary] => [format] => 2 [safe_value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124085 [uid] => 2032 [filename] => n_neuroscienze.jpg [uri] => public://n_neuroscienze_0.jpg [filemime] => image/jpeg [filesize] => 72438 [status] => 1 [timestamp] => 1698147067 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => neuroscience [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM [format] => [safe_value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2023-11-03T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 439764 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124085 [uid] => 2032 [filename] => n_neuroscienze.jpg [uri] => public://n_neuroscienze_0.jpg [filemime] => image/jpeg [filesize] => 72438 [status] => 1 [timestamp] => 1698147067 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => neuroscience [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 124085 [uid] => 2032 [filename] => n_neuroscienze.jpg [uri] => public://n_neuroscienze_0.jpg [filemime] => image/jpeg [filesize] => 72438 [status] => 1 [timestamp] => 1698147067 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => neuroscience [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 439764 [uid] => 2032 [title] => Paolo Bonato, guest at the Seminars series organized by PNC and DNS [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104735 [type] => box_lancio_news [language] => it [created] => 1698147067 [changed] => 1698147067 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1698147067 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[summary] => [format] => 2 [safe_value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124085 [uid] => 2032 [filename] => n_neuroscienze.jpg [uri] => public://n_neuroscienze_0.jpg [filemime] => image/jpeg [filesize] => 72438 [status] => 1 [timestamp] => 1698147067 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => neuroscience [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM [format] => [safe_value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2023-11-03T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 439764 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM [format] => [safe_value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM ) ) [#formatter] => text_default [0] => Array ( [#markup] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Paolo Bonato, guest at the Seminars series organized by PNC and DNS [href] => node/104735 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Paolo Bonato, guest at the Seminars series organized by PNC and DNS ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 439764 [uid] => 2032 [title] => Paolo Bonato, guest at the Seminars series organized by PNC and DNS [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104735 [type] => box_lancio_news [language] => it [created] => 1698147067 [changed] => 1698147067 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1698147067 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[summary] => [format] => 2 [safe_value] =>

As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk entitled Precision Rehabilitation Interventions in Neurological Patients Undergoing Robot-Assisted Motor Training on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM (Via Orus 2 – Padova).

The talk will review the use of robotics in rehabilitation medicine with a focus on retraining motor function in patients with neurological conditions ranging from stroke to cerebral palsy. It will be argued that the prediction of patients’ response to robot-assisted motor training should account for the mechanisms underlying the short-term and long-term response of each patient to the forces generated by the robot. Finally, the talk will present preliminary results on sensory augmentation techniques aimed to boost (and potentially restore) the ability of patients to generate a motor adaptation to robot-exerted forces hence providing an opportunity to retrain the ability of patients to generate new or modify existing motor plans. 

The seminar will be held in English, and it is open to professors, researchers, lecturers, Ph.D. students, postdoctoral fellows and grant holders.

Attendance is free as long as places are available.

Further information: administration.pnc@unipd.it

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124085 [uid] => 2032 [filename] => n_neuroscienze.jpg [uri] => public://n_neuroscienze_0.jpg [filemime] => image/jpeg [filesize] => 72438 [status] => 1 [timestamp] => 1698147067 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 630 [width] => 1200 ) [height] => 630 [width] => 1200 [alt] => neuroscience [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( [und] => Array ( [0] => Array ( [value] => [format] => [safe_value] => ) ) ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM [format] => [safe_value] => As part of the seminars organized by the “Padua Neuroscience Center – PNC” together with the Department of Neuroscience, Paolo Bonato, Harvard Medical School and Spaulding Rehabilitation Hospital, will give a talk on November 2 at Fondazione Ricerca Biomedica Avanzata VIMM ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2023-11-03T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 439764 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Mar, 24/10/2023 ) ) )

Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 450666 [uid] => 2032 [title] => Doctoral degree awarding ceremony a.y. 2021/2022 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104731 [type] => box_lancio_news [language] => it [created] => 1698140820 [changed] => 1708930976 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1708930976 [revision_uid] => 102 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022.

The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022.

The ceremony, which can be attended by invitation only, is being streamed live.

Engineering
October 24, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Chemistry and Earth Science
October 24, 2023 - 3.30 p.m.
Aula Magna di Palazzo del Bo

Medicine and Psychology
October 25, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Mathematics and Physics
October 25, 2023 - 3.30 p.m.
Aula Magna of Palazzo del Bo

Biology, Agricultural and Veterinary Medicine
October 26, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

The University of Padua coordinates 40 separate PhD Programs, 30 of which are in English.

PhD programs are divided by macro areas: Mathematics and Physics; Chemistry and Earth Sciences; Biology, Agricultural and Veterinary Medicine; Medicine and Psychology; Engineering; Humanities and Pedagogy; and Social Disciplines.

The goal of a doctoral course is the acquisition of proper methodology for advanced scientific research, which can be practiced at universities, public agencies or private entities, or the acquisition of professionalism of the highest level.

[summary] => [format] => 2 [safe_value] =>

On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022.

The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022.

The ceremony, which can be attended by invitation only, is being streamed live.

Engineering
October 24, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Chemistry and Earth Science
October 24, 2023 - 3.30 p.m.
Aula Magna di Palazzo del Bo

Medicine and Psychology
October 25, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Mathematics and Physics
October 25, 2023 - 3.30 p.m.
Aula Magna of Palazzo del Bo

Biology, Agricultural and Veterinary Medicine
October 26, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

The University of Padua coordinates 40 separate PhD Programs, 30 of which are in English.

PhD programs are divided by macro areas: Mathematics and Physics; Chemistry and Earth Sciences; Biology, Agricultural and Veterinary Medicine; Medicine and Psychology; Engineering; Humanities and Pedagogy; and Social Disciplines.

The goal of a doctoral course is the acquisition of proper methodology for advanced scientific research, which can be practiced at universities, public agencies or private entities, or the acquisition of professionalism of the highest level.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124080 [uid] => 2032 [filename] => n_dottorato.jpg [uri] => public://n_dottorato_3.jpg [filemime] => image/jpeg [filesize] => 38476 [status] => 1 [timestamp] => 1698140820 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 302 [width] => 677 ) [height] => 302 [width] => 677 [alt] => phd [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022. The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022 [format] => [safe_value] => On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022. The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022 ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2023-10-27T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 450666 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022.

The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022.

The ceremony, which can be attended by invitation only, is being streamed live.

Engineering
October 24, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Chemistry and Earth Science
October 24, 2023 - 3.30 p.m.
Aula Magna di Palazzo del Bo

Medicine and Psychology
October 25, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Mathematics and Physics
October 25, 2023 - 3.30 p.m.
Aula Magna of Palazzo del Bo

Biology, Agricultural and Veterinary Medicine
October 26, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

The University of Padua coordinates 40 separate PhD Programs, 30 of which are in English.

PhD programs are divided by macro areas: Mathematics and Physics; Chemistry and Earth Sciences; Biology, Agricultural and Veterinary Medicine; Medicine and Psychology; Engineering; Humanities and Pedagogy; and Social Disciplines.

The goal of a doctoral course is the acquisition of proper methodology for advanced scientific research, which can be practiced at universities, public agencies or private entities, or the acquisition of professionalism of the highest level.

[summary] => [format] => 2 [safe_value] =>

On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022.

The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022.

The ceremony, which can be attended by invitation only, is being streamed live.

Engineering
October 24, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Chemistry and Earth Science
October 24, 2023 - 3.30 p.m.
Aula Magna di Palazzo del Bo

Medicine and Psychology
October 25, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Mathematics and Physics
October 25, 2023 - 3.30 p.m.
Aula Magna of Palazzo del Bo

Biology, Agricultural and Veterinary Medicine
October 26, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

The University of Padua coordinates 40 separate PhD Programs, 30 of which are in English.

PhD programs are divided by macro areas: Mathematics and Physics; Chemistry and Earth Sciences; Biology, Agricultural and Veterinary Medicine; Medicine and Psychology; Engineering; Humanities and Pedagogy; and Social Disciplines.

The goal of a doctoral course is the acquisition of proper methodology for advanced scientific research, which can be practiced at universities, public agencies or private entities, or the acquisition of professionalism of the highest level.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022.

The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022.

The ceremony, which can be attended by invitation only, is being streamed live.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 450666 [uid] => 2032 [title] => Doctoral degree awarding ceremony a.y. 2021/2022 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104731 [type] => box_lancio_news [language] => it [created] => 1698140820 [changed] => 1708930976 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1708930976 [revision_uid] => 102 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022.

The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022.

The ceremony, which can be attended by invitation only, is being streamed live.

Engineering
October 24, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Chemistry and Earth Science
October 24, 2023 - 3.30 p.m.
Aula Magna di Palazzo del Bo

Medicine and Psychology
October 25, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Mathematics and Physics
October 25, 2023 - 3.30 p.m.
Aula Magna of Palazzo del Bo

Biology, Agricultural and Veterinary Medicine
October 26, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

The University of Padua coordinates 40 separate PhD Programs, 30 of which are in English.

PhD programs are divided by macro areas: Mathematics and Physics; Chemistry and Earth Sciences; Biology, Agricultural and Veterinary Medicine; Medicine and Psychology; Engineering; Humanities and Pedagogy; and Social Disciplines.

The goal of a doctoral course is the acquisition of proper methodology for advanced scientific research, which can be practiced at universities, public agencies or private entities, or the acquisition of professionalism of the highest level.

[summary] => [format] => 2 [safe_value] =>

On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022.

The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022.

The ceremony, which can be attended by invitation only, is being streamed live.

Engineering
October 24, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Chemistry and Earth Science
October 24, 2023 - 3.30 p.m.
Aula Magna di Palazzo del Bo

Medicine and Psychology
October 25, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Mathematics and Physics
October 25, 2023 - 3.30 p.m.
Aula Magna of Palazzo del Bo

Biology, Agricultural and Veterinary Medicine
October 26, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

The University of Padua coordinates 40 separate PhD Programs, 30 of which are in English.

PhD programs are divided by macro areas: Mathematics and Physics; Chemistry and Earth Sciences; Biology, Agricultural and Veterinary Medicine; Medicine and Psychology; Engineering; Humanities and Pedagogy; and Social Disciplines.

The goal of a doctoral course is the acquisition of proper methodology for advanced scientific research, which can be practiced at universities, public agencies or private entities, or the acquisition of professionalism of the highest level.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124080 [uid] => 2032 [filename] => n_dottorato.jpg [uri] => public://n_dottorato_3.jpg [filemime] => image/jpeg [filesize] => 38476 [status] => 1 [timestamp] => 1698140820 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 302 [width] => 677 ) [height] => 302 [width] => 677 [alt] => phd [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022. The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022 [format] => [safe_value] => On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022. The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022 ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2023-10-27T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 450666 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124080 [uid] => 2032 [filename] => n_dottorato.jpg [uri] => public://n_dottorato_3.jpg [filemime] => image/jpeg [filesize] => 38476 [status] => 1 [timestamp] => 1698140820 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 302 [width] => 677 ) [height] => 302 [width] => 677 [alt] => phd [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 124080 [uid] => 2032 [filename] => n_dottorato.jpg [uri] => public://n_dottorato_3.jpg [filemime] => image/jpeg [filesize] => 38476 [status] => 1 [timestamp] => 1698140820 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 302 [width] => 677 ) [height] => 302 [width] => 677 [alt] => phd [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 450666 [uid] => 2032 [title] => Doctoral degree awarding ceremony a.y. 2021/2022 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104731 [type] => box_lancio_news [language] => it [created] => 1698140820 [changed] => 1708930976 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1708930976 [revision_uid] => 102 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022.

The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022.

The ceremony, which can be attended by invitation only, is being streamed live.

Engineering
October 24, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Chemistry and Earth Science
October 24, 2023 - 3.30 p.m.
Aula Magna di Palazzo del Bo

Medicine and Psychology
October 25, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Mathematics and Physics
October 25, 2023 - 3.30 p.m.
Aula Magna of Palazzo del Bo

Biology, Agricultural and Veterinary Medicine
October 26, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

The University of Padua coordinates 40 separate PhD Programs, 30 of which are in English.

PhD programs are divided by macro areas: Mathematics and Physics; Chemistry and Earth Sciences; Biology, Agricultural and Veterinary Medicine; Medicine and Psychology; Engineering; Humanities and Pedagogy; and Social Disciplines.

The goal of a doctoral course is the acquisition of proper methodology for advanced scientific research, which can be practiced at universities, public agencies or private entities, or the acquisition of professionalism of the highest level.

[summary] => [format] => 2 [safe_value] =>

On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022.

The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022.

The ceremony, which can be attended by invitation only, is being streamed live.

Engineering
October 24, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Chemistry and Earth Science
October 24, 2023 - 3.30 p.m.
Aula Magna di Palazzo del Bo

Medicine and Psychology
October 25, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Mathematics and Physics
October 25, 2023 - 3.30 p.m.
Aula Magna of Palazzo del Bo

Biology, Agricultural and Veterinary Medicine
October 26, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

The University of Padua coordinates 40 separate PhD Programs, 30 of which are in English.

PhD programs are divided by macro areas: Mathematics and Physics; Chemistry and Earth Sciences; Biology, Agricultural and Veterinary Medicine; Medicine and Psychology; Engineering; Humanities and Pedagogy; and Social Disciplines.

The goal of a doctoral course is the acquisition of proper methodology for advanced scientific research, which can be practiced at universities, public agencies or private entities, or the acquisition of professionalism of the highest level.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124080 [uid] => 2032 [filename] => n_dottorato.jpg [uri] => public://n_dottorato_3.jpg [filemime] => image/jpeg [filesize] => 38476 [status] => 1 [timestamp] => 1698140820 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 302 [width] => 677 ) [height] => 302 [width] => 677 [alt] => phd [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022. The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022 [format] => [safe_value] => On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022. The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022 ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2023-10-27T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 450666 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022. The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022 [format] => [safe_value] => On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022. The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022 ) ) [#formatter] => text_default [0] => Array ( [#markup] => On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022. The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022 ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Doctoral degree awarding ceremony a.y. 2021/2022 [href] => node/104731 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Doctoral degree awarding ceremony a.y. 2021/2022 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 450666 [uid] => 2032 [title] => Doctoral degree awarding ceremony a.y. 2021/2022 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 104731 [type] => box_lancio_news [language] => it [created] => 1698140820 [changed] => 1708930976 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1708930976 [revision_uid] => 102 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022.

The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022.

The ceremony, which can be attended by invitation only, is being streamed live.

Engineering
October 24, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Chemistry and Earth Science
October 24, 2023 - 3.30 p.m.
Aula Magna di Palazzo del Bo

Medicine and Psychology
October 25, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Mathematics and Physics
October 25, 2023 - 3.30 p.m.
Aula Magna of Palazzo del Bo

Biology, Agricultural and Veterinary Medicine
October 26, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

The University of Padua coordinates 40 separate PhD Programs, 30 of which are in English.

PhD programs are divided by macro areas: Mathematics and Physics; Chemistry and Earth Sciences; Biology, Agricultural and Veterinary Medicine; Medicine and Psychology; Engineering; Humanities and Pedagogy; and Social Disciplines.

The goal of a doctoral course is the acquisition of proper methodology for advanced scientific research, which can be practiced at universities, public agencies or private entities, or the acquisition of professionalism of the highest level.

[summary] => [format] => 2 [safe_value] =>

On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022.

The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022.

The ceremony, which can be attended by invitation only, is being streamed live.

Engineering
October 24, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Chemistry and Earth Science
October 24, 2023 - 3.30 p.m.
Aula Magna di Palazzo del Bo

Medicine and Psychology
October 25, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

Mathematics and Physics
October 25, 2023 - 3.30 p.m.
Aula Magna of Palazzo del Bo

Biology, Agricultural and Veterinary Medicine
October 26, 2023 - 10.30 a.m.
Aula Magna of Palazzo del Bo

The University of Padua coordinates 40 separate PhD Programs, 30 of which are in English.

PhD programs are divided by macro areas: Mathematics and Physics; Chemistry and Earth Sciences; Biology, Agricultural and Veterinary Medicine; Medicine and Psychology; Engineering; Humanities and Pedagogy; and Social Disciplines.

The goal of a doctoral course is the acquisition of proper methodology for advanced scientific research, which can be practiced at universities, public agencies or private entities, or the acquisition of professionalism of the highest level.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124080 [uid] => 2032 [filename] => n_dottorato.jpg [uri] => public://n_dottorato_3.jpg [filemime] => image/jpeg [filesize] => 38476 [status] => 1 [timestamp] => 1698140820 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 302 [width] => 677 ) [height] => 302 [width] => 677 [alt] => phd [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022. The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022 [format] => [safe_value] => On October 24, 25 and 26 the Aula Magna of Palazzo del Bo hosts Doctoral degree awarding ceremony a.y. 2021/2022. The ceremony involves 443 researchers who received their PhD academic qualification at the University of Padua between December 2021 and November 2022 ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [value2] => 2023-10-27T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 2 [current_revision_id] => 450666 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2023-10-24T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Mar, 24/10/2023 ) ) )